Global Venous Thromboembolism: Epidemiology and Patient-Based Market 2015-2024 - The Growth Drivers and Resistors for the NOAC and Vitamin K Antagonist Drug Classes - Research and Markets

DUBLIN, August 17, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Venous Thromboembolism: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis" report to their offering.

The value of the venous thromboembolism (VTE) market is expected to grow rapidly as the approvals of antidotes for the novel oral anticoagulant (NOAC) drugs are secured and physician acceptance of these drugs rises.

This report addresses the following questions:

- Which patient subgroups and markets will have the largest impact on VTE sales?

- How will the approval of antidotes affect the uptake of the NOAC drug class?

- What are the most commonly prescribed therapies for VTE patients?

- How will Pradaxa's first-to-market antidote affect the market shares of other NOAC molecules?

- What are the growth drivers and resistors for the NOAC and vitamin K antagonist drug classes during 2015-24?

- How do the prescribing trends correlate with current recommendations from clinical guidelines?

Key Topics Covered:

FORECAST: VENOUS THROMBOEMBOLISM

- Executive Summary

- Market Overview and Trends

- Market Definition and Methodology

- Eliquis (apixaban)

- Pradaxa (dabigatran)

- Savaysa (edoxaban)

- Xarelto (rivaroxaban)

- Primary Research Methodology

TREATMENT: VENOUS THROMBOEMBOLISM

- Executive Summary

- Primary Research Methodology

- Disease Definition and Diagnosis

- Country Treatment Trees

- Current Treatment Options

- Prescribing Trends

EPIDEMIOLOGY: VENOUS THROMBOEMBOLISM

- Executive Summary

- Sources and Methodology

- Forecast

- Epidemiologist Insight.

- Strengths and Limitations

MARKETED DRUGS: VENOUS THROMBOEMBOLISM

- Executive Summary

- Product Overview

- Product profile: Coumadin

- Product profile: Eliquis

- Product profile: Lovenox

- Product profile: Pradaxa

- Product profile: Savaysa

- Product profile: Xarelto

PIPELINE: VENOUS THROMBOEMBOLISM

- Executive Summary

- Clinical Pipeline Overview

- Target Product Profile

- Product profile (late stage): betrixaban

For more information about this report visit http://www.researchandmarkets.com/research/gt4c2p/venous

Related Topics: Cardiovascular Drugs

Media Contact:

Laura Wood, Senior Manager

[email protected] 

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com